Active substance
Sertaconazole
- SFDA 1
- US FDA 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DERMOFIX 2% CREAM | 2 % | Cream · Topical | 1 Tube | SAR 17.00 | NCE · Prescription | FERRER INTERNATIONAL | Valid |
Indications — CHI Daman Drug Formulary
SEBORRHEIC DERMATITIS; TINEA CORPORIS, TINEA CRURIS, AND TINEA PEDIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ERTACZO | 2% | cream · topical | LACER PHARMA | Prescription | 10 Dec 2003 |
Safety signals and safety-related labeling changes
- US FDA 17 Dec 2020 ERTACZO — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.